Your Name

Address, WA | +1 (000) 000-0000 | [email protected] | Linkedin.com/in/yourname

Pharmaceutical Board Member/Consultant

Highly accomplished and resourceful executive and board member with a distinguished career spanning over three decades in the biotechnology and pharmaceutical industries. Instrumental in the seamless integration of high-profile acquisitions while optimizing operational efficiency, rescuing clinical programs, and strategically managing finances. Adept at securing strategic partnerships with industry giants, negotiating valuable licenses, and transforming the Intellectual Property program. Extensive experience in leading transformative initiatives, including a comprehensive corporate strategy overhaul and successful investor and partner engagement to promise dialogues and significant investments.

PROFESSIONAL EXPERIENCE

ABC Therapeutics | Radnor, PA 2023 to Present

Board Member & Consultant

Orchestrate a comprehensive overhaul of the company's strategy, pipeline prioritization, messaging, and corporate presentation deck in collaboration with the Board.

▪          Devised and executed a far-reaching investor and strategic partner campaign, representing the company at multiple BD and investor conferences, resulting in the initiation of numerous promising investor and strategic partner dialogues.

▪          Assumed a pivotal role in engaging with critical potential investor groups and strategic partners, resulting in multiple subscriptions to the company’s ongoing $8MM notes round and sparking fresh discussions with potential strategic allies.

▪          Conducted outreach and follow-up with investors and strategic partners while working closely with the CEO on diverse corporate matters, including licensing negotiations, budgeting, and operational facets.

Pfizer Inc. | Baltimore, MD 2021 to 2023

Chief Executive Officer | Board Member

Administrated a transformative cultural shift, restructuring half the 20-person team, and steering them to reach key milestones. Initiated a pilot program utilizing a camera-equipped van for home visits to further enhance compliance. Developed a pivotal trial protocol to streamline product registration in Europe and the US. Collaborated with regulators to onboard new clinical sites, complete enrollment, and revive a stalled pivotal trial.

▪          Surpassed the prior year's results and reached a company milestone by doubling patient recruitment within a few months.

▪          Boosted patient compliance through collaborative efforts with clinicians, the Contract Research Organization (CRO), and the team.

▪          Successfully obtained protocol amendments from European Institutional Review Boards (IRBs) to enable incentive payments, thereby improving patient attendance at follow-up visits.

▪          Attained strong patient compliance, met demographic inclusion goals, and successfully reached the primary non-inferiority endpoint with a significant p-value of .025

▪          Initiated talks with 12 partners, secured $3M for exploration, negotiated with a Chinese distributor, and generated multiple term sheets from industry giants like Merz, Galderma, Hugel, and Sinclair/Huadong.

▪          Achieved trial's primary endpoint, resulting in the cancellation of all other R&D expenses and a shift toward cell therapy.

▪          Drove initiatives to enhance QC and manufacturing/documentation systems to attain the company's initial ISO 13485 certification

▪          Secured $3 million in convertible note financing in Q1 and implemented an efficient licensing and strategic process.

Sami Sami | Research Triangle Park, NC 2020 to 2021

Sr. Vice President

Directed the CNS program by playing a pivotal role in supporting a dual-track IPO/M&A process that culminated in Bayer Pharma's remarkable $4B+ acquisition of Ask. Demonstrated exceptional leadership by overseeing the seamless integration of two significant CNS acquisitions, Brain Vectis (Paris, FR), and Brain Neurotherapy Bio (Columbus, OH).

▪          Led cross-functional teams in a concerted effort to standardize and enhance MRI-guided deep brain injection protocols, devices, and software to improve precision and efficiency in the company’s operations.

▪          Rescued and re-energized stalled clinical programs in conditions like Parkinson's, MSA, Huntington's, and Alzheimer's to propel them toward greater success and advancements.

▪          Implemented a strategic financial maneuver by reducing planned spending by $25M+ on non-priority legacy programs.

Allen Border Science Institute | Seattle, WA 2016 to 2020

Sr. Director Business Development | Founding Board Member

Sourced and skillfully negotiated multi-indication CNS gene therapy collaborations with industry giants BioMarin and Ask Bio to cement strategic partnerships that hold immense promise. Displayed exceptional negotiation prowess by securing a valuable license for machine learning algorithms and neural networks designed for cutting-edge 3D live cell imaging from GE Healthcare.

▪          Pioneered the implementation of a robust Intellectual Property (IP) program in a previously indifferent environment which resulted in a remarkable surge in disclosures, from just one per year to exceeding 40 per year.

▪          Co-invented a landmark international patent filing that encompasses the use of AI and neural networks for a non-invasive and label-free 3D visualization method, a groundbreaking innovation with applications in cell therapy research and development, as well as in-line manufacturing quality control.

EARLIER EXPERIENCE & OTHER BOARD APPOINTMENTS

BEAT BioTherapeutics | Seattle, WA 2013 to 2018

Chief Executive Officer | Member of the Board

PTC Therapeutics, Inc. | South Plainfield, NJ 2003 to 2015

Board Member and Audit Committee Chairman

Cardero Therapeutics | Los Altos Hills, CA 2010 to 2012

Chairman

Vaccinogen Inc. | Frederick, MD 2010 to 2012

CEO | President | Director

Raven Biotechnologies | San Francisco, CA 2005 to 2008

CEO | President | Director

Vulcan Capital | Seattle, WA 2002 to 2007

Managing Director and Investment Committee Member

Governed the origination and successful oversight of the Series A funding round for BiPar, based in San Francisco, California while managing a highly lucrative exit strategy through the sale of BiPar to Sanofi which resulted in a remarkable return on investment, nearly 10 times the initial capital.

▪          Contributed as a key member of the Board for the PTC Therapeutics investment by adeptly administrating another substantial exit with impressive results.

▪          Achieved a remarkable track record of fund performance by ranking among the top 10% of venture funds in the United States, underscoring a strong history of delivering exceptional returns on investments.

CEO and Board Member, Oxford GlycoSciences | President and COO/Member of the Board, Immunex

MAJOR DRUGS APPROVAL

▪          VYVYVY: Oversaw and successfully executed a £175 million IPO and subsequent NASDAQ listing to bolster developmental initiatives as well as established and managed a high-performing global specialty sales team.

▪          XYTT: Obtained conditional approval in the EU for mitochondria cellular Dystrophy.

▪          SZSS: Played a key role in the development of Roche's leading Spinal Muscular Atrophy drug, originally developed by PTCT and later licensed to Roche.

▪          SCSC: Achieved approval for the treatment of neutropenia while undertaking the challenging responsibility of establishing both clinical and commercial manufacturing facilities.

▪          VDCD: Approved one of the leading disease-modifying drugs for the treatment of Rheumatoid Arthritis.

EDUCATION

Master of Business Administration in Finance – University of Washington, Seattle, WA